237 related articles for article (PubMed ID: 33830942)
1. MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose.
Hage M; Janot C; Salenave S; Chanson P; Kamenický P
Eur J Endocrinol; 2021 May; 184(6):R261-R268. PubMed ID: 33830942
[TBL] [Abstract][Full Text] [Related]
2. KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomas.
Chasseloup F; Regazzo D; Tosca L; Proust A; Kuhn E; Hage M; Jublanc C; Mokhtari K; Dalle Nogare M; Avallone S; Ceccato F; Tachdjian G; Salenave S; Young J; Gaillard S; Parker F; Boch AL; Chanson P; Bouligand J; Occhi G; Kamenický P
Eur J Endocrinol; 2024 Feb; 190(2):173-181. PubMed ID: 38330165
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly.
Scaroni C; Albiger N; Daniele A; Dassie F; Romualdi C; Vazza G; Regazzo D; Ferraù F; Barresi V; Maffeis V; Gardiman MP; Cannavò S; Maffei P; Ceccato F; Losa M; Occhi G
J Clin Endocrinol Metab; 2019 Mar; 104(3):856-862. PubMed ID: 30285115
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
5. The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells.
Occhi G; Losa M; Albiger N; Trivellin G; Regazzo D; Scanarini M; Monteserin-Garcia JL; Fröhlich B; Ferasin S; Terreni MR; Fassina A; Vitiello L; Stalla G; Mantero F; Scaroni C
J Neuroendocrinol; 2011 Jul; 23(7):641-9. PubMed ID: 21554434
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylator Phenotype and Ectopic GIP Receptor in GNAS Mutation-Negative Somatotropinomas.
Hage M; Chaligné R; Viengchareun S; Villa C; Salenave S; Bouligand J; Letouzé E; Tosca L; Rouquette A; Tachdjian G; Parker F; Lombès M; Lacroix A; Gaillard S; Chanson P; Kamenický P
J Clin Endocrinol Metab; 2019 May; 104(5):1777-1787. PubMed ID: 30376114
[TBL] [Abstract][Full Text] [Related]
7. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype.
Lee CC; Vance ML; Lopes MB; Xu Z; Chen CJ; Sheehan J
Pituitary; 2015 Jun; 18(3):326-34. PubMed ID: 24925503
[TBL] [Abstract][Full Text] [Related]
9. The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of
Regazzo D; Losa M; Albiger NM; Terreni MR; Vazza G; Ceccato F; Emanuelli E; Denaro L; Scaroni C; Occhi G
Eur J Endocrinol; 2017 May; 176(5):543-553. PubMed ID: 28179449
[TBL] [Abstract][Full Text] [Related]
10. Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome.
Vortmeyer AO; Gläsker S; Mehta GU; Abu-Asab MS; Smith JH; Zhuang Z; Collins MT; Oldfield EH
J Clin Endocrinol Metab; 2012 Jul; 97(7):2404-13. PubMed ID: 22564667
[TBL] [Abstract][Full Text] [Related]
11. Serum phosphate: Does it more closely reflect the true state of acromegaly?
Xie T; Tian P; Wu S; Zhang X; Liu T; Gu Y; Sun C; Hu F
J Clin Neurosci; 2020 Jan; 71():26-31. PubMed ID: 31859176
[TBL] [Abstract][Full Text] [Related]
12. Revisiting the Role of Insulin-like Growth Factor-1 Measurement After Surgical Treatment of Acromegaly.
Jung IH; Choi S; Ku CR; Lee SG; Lee EJ; Kim SH; Kim EH
J Clin Endocrinol Metab; 2021 Jun; 106(7):e2589-e2599. PubMed ID: 33738470
[TBL] [Abstract][Full Text] [Related]
13. Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor.
Oba-Yamamoto C; Kameda H; Miyoshi H; Sekizaki T; Takase T; Yanagimachi T; Fujita Y; Nomoto H; Cho KY; Nakamura A; Nagai S; Atsumi T
Intern Med; 2021; 60(15):2375-2383. PubMed ID: 34334589
[TBL] [Abstract][Full Text] [Related]
14. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
15. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?
Garcia EA; Trivellin G; Aflorei ED; Powell M; Grieve J; Alusi G; Pobereskin L; Shariati B; Cudlip S; Roncaroli F; Mendoza N; Grossman AB; Harper EA; Korbonits M
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1918-26. PubMed ID: 24152687
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
[TBL] [Abstract][Full Text] [Related]
17. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A
Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395
[TBL] [Abstract][Full Text] [Related]
18. Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly.
Umahara M; Okada S; Ohshima K; Mori M
Endocr J; 2003 Oct; 50(5):643-50. PubMed ID: 14614222
[TBL] [Abstract][Full Text] [Related]
19. Modern approach to resistant acromegaly.
Giustina A; di Filippo L; Uygur MM; Frara S
Endocrine; 2023 May; 80(2):303-307. PubMed ID: 36790521
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
